IN8bio reports Q4 2023 net loss of $7.6M and cash of $21.3M; highlights positive clinical data

IN8BIO, INC.

Q4 2023 net loss $7.6M ($0.22 per share) vs Q4 2022 net loss $7.8M ($0.32 per share).
Full-year 2023 net loss $30.0M ($1.00 per share); R&D expenses increased to $16.8M.
Cash $21.3M as of Dec 31, 2023 vs $18.2M a year earlier; private placement extended runway into 1Q 2025.
100% of evaluable leukemia patients (n=10) in INB-100 Phase 1 remained in remission as of Nov 3, 2023.
Appointed Dr. Corinne Epperly, M.D., M.P.H. to Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IN8BIO, INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: net income a net loss of $7.6 million, or $0.22 per basic and diluted common share, for the three months ended December 31, 2023, EPS $0.22 per basic and diluted common share.

Period: the fourth quarter and fiscal year ended December 31, 2023
Net income: a net loss of $7.6 million, or $0.22 per basic and diluted common share, for the three months ended December 31, 2023
EPS: $0.22 per basic and diluted common share
Result: reported results

Exact text from the filing

IN8bio, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-031478

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.